Post-effective Amendment to an S-8 Filing (s-8 Pos)
30 March 2016 - 4:40AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 29,
2016
Registration No:
333-03895
333-95129
333-95127
333-91386
333-134608
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
Post-Effective
Amendment No. 1 to Registration Statement No. 333-03895
Post-Effective
Amendment No. 2 to Registration Statement No. 333-95129
Post-Effective
Amendment No. 1 to Registration Statement No. 333-95127
Post-Effective
Amendment No. 2 to Registration Statement No. 333-91386
Post-Effective
Amendment No. 2 to Registration Statement No. 333-134608
UNDER
THE
SECURITIES ACT OF 1933
Pathfinder
Cell Therapy, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware
|
|
14-1745197
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer identification No.)
|
12
Bow Street
Cambridge,
Massachusetts 02138
(Address
of principal executive offices and Zip Code)
(617)
245-0849
(Registrant's
telephone number, including area code)
2006
STOCK OPTION PLAN
2001
NONQUALIFIED STOCK OPTION PLAN
2000
NONQUALIFIED STOCK OPTION PLAN
1992
STOCK OPTION PLAN
CERTAIN
NON-PLAN STOCK OPTIONS
(full
title of plans)
Richard
L. Franklin, M.D., Ph.D.
12
Bow Street
Cambridge,
Massachusetts 02138
(617)
245-0289
(Name,
address, and telephone number of agent for service)
With
a copy to
:
Keith
M. Moskowitz, Esq.
Eilenberg
& Krause LLP
11
East 44
th
Street
New
York, New York 10017
Tel.
(212) 986-9700
Fax
(212) 986-2399
EXPLANATORY
NOTE
Pathfinder
Cell Therapy, Inc. (the “Company”) is hereby filing this Post-Effective Amendment to each of its Registration Statements
on Form S-8
(registration nos. 333-03895; 333-95129,
333-9512, 333-91386, 333-134608) (collectively, the “Registration Statements”)
to
remove from registration all securities of the Company that remain unsold under the Registration Statements.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has duly caused this Post-Effective Amendment to its Registration Statements on
Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts,
on March 29, 2016.
|
|
PATHFINDER CELL THERAPY, INC.
|
|
|
|
|
|
|
By:
|
/s/ Richard L. Franklin, M.D., Ph.D.
|
|
|
|
Richard L. Franklin, M.D., Ph.D.
Chief Executive Officer and President
|
Pursuant to the requirements of the Securities
Act of 1933, this Post-Effective Amendment to the Registration Statements on Form S-8 has been signed below by the following persons
in the capacities and on the dates indicated:
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/
Richard L. Franklin, M.D., Ph.D.
|
|
Chief
Executive Officer, President and Director
|
|
March
29, 2016
|
|
Richard
L. Franklin, M.D., Ph.D.
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/
John Benson
|
|
Chief
Financial Officer
|
|
March
29, 2016
|
|
John
Benson
|
|
(Principal
Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/
Joerg Gruber
|
|
Chairman
of the Board of Directors
|
|
March
29, 2016
|
|
Joerg
Gruber
|
|
|
|
|
|
|
|
|
|
|
|
/s/
John L. Brooks III
|
|
Director
|
|
March
29, 2016
|
|
John
L. Brooks III
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Zen Chu
|
|
Director
|
|
March
29, 2016
|
|
Zen
Chu
|
|
|
|
|
|
|
|
|
|
|
|
/s/
John Alam, M.D.
|
|
Director
|
|
March
29, 2016
|
|
John
Alam, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/
Brock Reeve
|
|
Director
|
|
March
29, 2016
|
|
Brock
Reeve
|
|
|
|
|
Pathfinder Cell Therapy (CE) (USOTC:PFND)
Historical Stock Chart
From Oct 2024 to Dec 2024
Pathfinder Cell Therapy (CE) (USOTC:PFND)
Historical Stock Chart
From Dec 2023 to Dec 2024
